Houston, TXFounded 20204+ employeesPrivate
$5.1M raisedSeed· last: grant (Aug 2025)· 7 rounds
Backed by(8 investors)
At CellChorus, we apply artificial intelligence to evaluate thousands of microscopy videos in parallel to evaluate how immune cells move, interact and perform over time. This allows our customers to discover, develop, manufacture and deliver cell therapies, antibodies, vaccines and other novel therapies faster, at lower expense, and with higher rates of success. Our customers include top-25 biopharma companies and seed-stage biotechs that are developing cell therapies, antibody therapeutics and vaccines (including one of the few companies with an approved CAR T cell therapy). Hear from the team at https://www.youtube.com/watch?v=IE9x_tm0XnI
